Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/139006
Full metadata record
DC FieldValueLanguage
dc.creatorLuís, C
dc.creatorCastaño-Guerrero, Y
dc.creatorSoares, R
dc.creatorSales, G
dc.creatorFernandes, R
dc.date.accessioned2022-01-10T09:59:01Z-
dc.date.available2022-01-10T09:59:01Z-
dc.date.issued2019
dc.identifier.issn2409-9279
dc.identifier.urihttps://hdl.handle.net/10216/139006-
dc.description.abstractDoxorubicin (DOXO) is an adjuvant chemotherapy agent and is also commonly used in cell biology research. Cytotoxic assays in cell culture are frequently used in order to stablish drug concentrations that are useful for controlling cell proliferation. One common cytotoxic method used is 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT). Our present research aims to support future studies in engaging MTT assay using DOXO that exhibits a strong red coloration and fluorescence, and so it is assumed that DOXO may interfere with commonly used colorimetric assays such as MTT. The interference of DOXO in the MTT determination was evaluated in a Breast Cancer cell line Michigan Cancer Foundation-7 (MCF-7). The interference was evaluated by means of spectroscopic methods in particular spectrophometry and fluorescence spectroscopy of MTT and DOXO. We postulate that the medium and the MTT reagent itself can interfere on the metabolic activity method, so in order to achieve better results, DMEM was replaced by a neutral buffer like Phosphate-buffered saline (PBS). This protocol may be extremely useful in future studies involving DOXO.
dc.description.sponsorshipRúben Fernandes acknowledges, on the behalf of the authors, the funding entities. Carla Luís was supported by a scholarship with the reference SAICT2016/FEDER/BIO4DIA/BTI under the supervision of Dr. Rúben Fernandes. This work was also partially supported by the grant "IBEROS - Instituto de Bioengenharia em Rede para o envelhecimento saudável", 0245-IBEROS-1-E, cofinanced by the program INTERREG V-A POCTEP through FEDER to BIL/IBEROS-BioMark/03 developed under the supervision of Dr. Goreti Sales. This work was also supported by FCT - Fundação para a Ciência e Tecnologia (REF UID/BIM/04293/2013), by grants NORTE-01-0145-FEDER-000012, SAICT-POL/24325/2016, and SAICT-POL/24358/2016 to Drs. Goreti Sales, Raquel Soares, and Rúben Fernandes.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofMethods and Protocols, vol.2(2), p. 1-5
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleAvoiding the interference of doxorubicin with mtt measurements on the mcf-7 breast cancer cell line
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.3390/mps2020029
dc.relation.publisherversionhttps://www.mdpi.com/2409-9279/2/2/29
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.3390-mps2020029.pdf549.89 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons